Dutogliptin Free Base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 413970

CAS#: 852329-66-9 (free base)

Description: Dutogliptin Free Base is an orally available, potent, and selective di-peptidyl peptidase 4/DPP4 inhibitor that improves glycemic control in type 2 diabetic patients.

Chemical Structure

img
Dutogliptin Free Base
CAS# 852329-66-9 (free base)
Instruction

Theoretical Analysis

MedKoo Cat#: 413970
Name: Dutogliptin Free Base
CAS#: 852329-66-9 (free base)
Chemical Formula: C10H20BN3O3
Exact Mass: 241.16
Molecular Weight: 241.090
Elemental Analysis: C, 49.82; H, 8.36; B, 4.48; N, 17.43; O, 19.91

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 852329-66-9 (free base)   890402-81-0 (tartrate)  

Synonym: Dutogliptin Free Base; PHX 1149; PHX-1149; PHX1149

IUPAC/Chemical Name: Boronic acid, ((2R)-1-(((3R)-3-pyrrolidinylamino)acetyl)-2-pyrrolidinyl)-

InChi Key: DVJAMEIQRSHVKC-BDAKNGLRSA-N

InChi Code: InChI=1S/C10H20BN3O3/c15-10(7-13-8-3-4-12-6-8)14-5-1-2-9(14)11(16)17/h8-9,12-13,16-17H,1-7H2/t8-,9+/m1/s1

SMILES Code: O=C(N1[C@H](B(O)O)CCC1)CN[C@H]2CNCC2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 241.09 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Johnson KM. Dutogliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus. Curr Opin Investig Drugs. 2010 Apr;11(4):455-63. PMID: 20336594.

2: Buchtele N, Schwameis M, Schoergenhofer C, Derhaschnig U, Firbas C, Karch R, Nix D, Schenk R, Jilma B. Safety, tolerability, pharmacokinetics and pharmacodynamics of parenterally administered dutogliptin: A prospective dose- escalating trial. Br J Clin Pharmacol. 2020 May;86(5):979-990. doi: 10.1111/bcp.14208. Epub 2020 Feb 11. PMID: 31912513; PMCID: PMC7163368.

3: Pattzi HM, Pitale S, Alpizar M, Bennett C, O'Farrell AM, Li J, Cherrington JM, Guler HP; PHX1149-PROT202 Study Group. Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010 Apr;12(4):348-55. doi: 10.1111/j.1463-1326.2010.01195.x. PMID: 20380656.

4: Marier JF, Mouksassi MS, Gosselin NH, Li J. Population pharmacokinetic analysis of dutogliptin, a selective dipeptidyl peptidase-4 inhibitor. Clin Pharmacol Drug Dev. 2014 Jul;3(4):297-304. doi: 10.1002/cpdd.87. Epub 2014 Feb 10. PMID: 27128836.

5: Li J, Klemm K, O'Farrell AM, Guler HP, Cherrington JM, Schwartz S, Boyea T. Evaluation of the potential for pharmacokinetic and pharmacodynamic interactions between dutogliptin, a novel DPP4 inhibitor, and metformin, in type 2 diabetic patients. Curr Med Res Opin. 2010 Aug;26(8):2003-10. doi: 10.1185/03007995.2010.491266. PMID: 20583949.

6: Wang B, Sun Y, Sang Y, Liu X, Liang J. Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: A system review and meta-analysis. Medicine (Baltimore). 2018 Nov;97(46):e12633. doi: 10.1097/MD.0000000000012633. PMID: 30431561; PMCID: PMC6257459.

7: von Lewinski D, Selvanayagam JB, Schatz RA, Jilma B, Kubica J, Povsic TJ, Nix D, Henauer S, Wallner M; REC-DUT-002 study group. "Protocol for a phase 2, randomized, double-blind, placebo-controlled, safety and efficacy study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction": study protocol for a randomized controlled trial. Trials. 2020 Aug 26;21(1):744. doi: 10.1186/s13063-020-04652-0. PMID: 32843081; PMCID: PMC7448478.

8: Gallwitz B. Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy. Expert Opin Investig Drugs. 2011 Jun;20(6):723-32. doi: 10.1517/13543784.2011.576667. Epub 2011 Apr 18. PMID: 21500969.

9: Gale S, Croasdell G. 28th Annual JPMorgan Healthcare Conference--Forest Laboratories and Icagen. IDrugs. 2010 Mar;13(3):145-8. PMID: 20191426.

10: Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther. 2012 Jan;29(1):14-25. doi: 10.1007/s12325-011-0088-z. Epub 2011 Dec 22. PMID: 22215383.